What is Zacks Research’s Estimate for FOLD Q3 Earnings?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Research analysts at Zacks Research boosted their Q3 2025 EPS estimates for Amicus Therapeutics in a research report issued on Wednesday, October 16th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn $0.04 per share for the quarter, up from their previous estimate of $0.03. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.07) per share. Zacks Research also issued estimates for Amicus Therapeutics’ FY2025 earnings at $0.14 EPS.

FOLD has been the topic of several other reports. JPMorgan Chase & Co. decreased their price objective on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of Amicus Therapeutics in a research report on Friday, September 20th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Bank of America upped their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Morgan Stanley reduced their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.13.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $11.90 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of -24.29 and a beta of 0.69. Amicus Therapeutics has a 1-year low of $9.02 and a 1-year high of $14.57. The firm’s 50-day moving average price is $11.17 and its two-hundred day moving average price is $10.56.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company’s quarterly revenue was up 34.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.15) earnings per share.

Institutional Investors Weigh In On Amicus Therapeutics

Large investors have recently bought and sold shares of the company. Blue Trust Inc. increased its stake in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares in the last quarter. Headlands Technologies LLC bought a new stake in Amicus Therapeutics in the second quarter valued at approximately $89,000. Sage Capital Advisors llc bought a new stake in Amicus Therapeutics in the second quarter valued at approximately $103,000. Sanctuary Advisors LLC bought a new stake in Amicus Therapeutics in the second quarter valued at approximately $138,000. Finally, EntryPoint Capital LLC increased its stake in Amicus Therapeutics by 278.8% in the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 9,729 shares in the last quarter.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $10,382,718.34. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 22,500 shares of company stock worth $244,875 over the last ninety days. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.